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Abstract 
Objectives: To elucidate the effect of the biallelic somatic TSC2 mutations, identified 
in one adolescent patient, in renal cell carcinoma (RCC). Methods: Mutation analyses,  
immunohistochemistry and real-time polymerase chain reaction (PCR) were 
conducted. Results: Two novel somatic mutations of TSC2 in unilateral and solitary 
RCC samples from a 14-year-old female were identified. The pathological features 
suggest the tumor as a clear-cell renal cell carcinoma. In addition, 
immunohistochemistry revealed elevated levels of phosphorylated S6K1. Results 
from in vitro cellular experiments suggest that the mutant TSC2 proteins were quickly 
degraded and they failed to repress the phosphorylation of S6K1 and STAT3, which 
leads to constitutive activation of mTORC1 pathway and ultimately cause the 
development of RCC. Conclusions: Detecting TSC2 mutation in patients with early 
RCC onset would be beneficial and mTOR inhibitor could be a therapeutic option for 
TSC2 mutation-induced RCC. 
 
  
Introduction 
Renal cell carcinoma (RCC) represents about 90% of renal malignancies, which is the 
13th most common malignancy among all cancers. Approximately 2-3% of RCC 
occurs in patients with hereditary diseases including von Hippel-Lindau (VHL) 
syndrome, hereditary papillary renal cell carcinoma, and Birt-Hogg-Dube’ syndrome 
[1]
. In addition, 2-4% of tuberous sclerosis (TSC) patients suffer from RCC, which is 
higher than the estimated incidence among the general population. Multiple lines of 
evidence suggest that loss of function of either TSC1 or TSC2 could result in RCC 
[2-4]
. 
The TSC1 and TSC2 genes are located on 9q34 and 16q13.3, respectively [5]. The 
protein complex composed of hamartin and tuberin, which is translated from TSC1 
and TSC2 respectively, possesses GTPase activity responsible for turning GTP-Rheb 
to GDP-Rheb. Therefore, both TSC1 and TSC2 were also known as cancer 
suppressors partially due to their inhibitory role on mammalian target of rapamycin 
complex 1 (mTORC1). Mechanistically, loss-of-function mutations in TSC1 and/or 
TSC2 result in inactivation of the hamartin-tuberin complex and subsequently 
inactivate GTPase and ultimately lead to constitutive activation of the mTORC1 
pathway 
[3]
. TSC is an autosomal dominant disease and almost all organs in these 
patients were affected 
[5]
 characterized by facial angiofibroma, seizures, and cognitive 
disability. TSC also can cause renal lesions including renal cell carcinoma 
[6]
. Since 
the first reported RCC in a patient with TSC in 1986 
[7]
, numerous cases of RCC have 
been reported in familial TSC with germline mutations in either TSC1 or TSC2. 
However, cases of RCC due to a somatic mutation of TSC2 is relatively rare. Here we 
present a case of clear cell renal cell carcinoma (ccRCC) in an adolescent with two 
novel biallelic somatic mutations in TSC2. 
 
Material and Methods 
2.1 Patient presentation 
A 14-year-old female was referred to the Southwest Hospital on July 23, 2017, due to 
the finding of a mass in the upper pole of her left kidney identified during an 
ultrasound test. Kidney tumor was later diagnosed based on the abdominal computed 
tomography (CT) scan. The laboratory tests did not reveal any other notable 
abnormalities. A robot-assisted nephron-sparing enucleation was conducted on July 26, 
2017, with a da Vinci surgical system and a 3.0×3.0 cm mass was excised. No sign of 
recurrence nor metastasis was seen in repeat CT scans during the reexamination 
conducted nine months after the surgery. Based on the clinical manifestation 
[8]
, 
mutation analyses were performed to determine whether there are germline or somatic 
mutations responsible for the ccRCC. We collected both peripheral blood and tumor 
samples for mutation analyses. Mutations in several potential oncogenesis-associated 
genes (supplement table 1) were screened using ER-seq (Gene+, China). To confirm 
the TSC2 mutation, polymerase chain reaction (PCR) was conducted on the patient’s 
DNA with primers specifically designed for TSC gene amplification, the PCR 
products were sub-cloned into a pMD18-T vector (D103A, TAKARA, Shiga, Japan), 
and finally Sanger sequencing was conducted. The informed consent was obtained 
from the patient and their parents, and all procedures performed in this study were in 
accordance with the standards of institutional research committee, and approved by 
the Research Ethics Committee of Daping Hospital, Third Military Medical 
University. 
2.2 Immunohistochemistry  
Immunohistochemistry was conducted as described 
[9]
. After deparaffinization and 
rehydration, slices were retrieved and incubated with primary antibodies against 
TSC2 (Santa Cruz, USA), VHL (OriGene, MD, USA), phosphorylated S6K1(p-S6K1) 
(Cell Signaling Technology, USA), HIF1α (Abcam, USA), HIF2α (OriGene, MD, 
USA), EPO (Santa Cruz, USA), SDHB (Proteintech, USA) and VEGF (OriGene, MD, 
USA) followed by incubation with HRP-labeled goat anti-mouse/rabbit IgG. In 
addition, the samples from a patient with Von Hippel-Lindau syndrome were used as a 
positive control. 
2.3 Cell culture 
Rat uterine leiomyoma-derived Tsc2-null cells, kindly provided by Dr. Hongbing 
Zhang of Peking Union Medical College, were cultured in DMEM supplemented with 
10% fetal bovine serum (FBS) (Gibco) at 37
o
C with 5% CO2. 
2.4 Transient transfection 
Since the two mutations identified in this patient were not reported previously, the 
function of them was elusive. To identify the function, plasmids containing either 
TSC2 mutations or wild type TSC2 were constructed (Mutant 1: 
c.1039-1049delAAGAAGTATAG in exon 11, Mutant 2: c.2721insT in exon 24) and 
transiently transfected into TSC2-null cells with Lipofectamine 3000 reagent 
(Invitrogen).  
2.5 Western blotting 
Lysates were collected from cells transfected with different plasmids and separated on 
SDS-PAGE followed by western blotting assay described previously 
[10]
 using the 
primary antibodies against TSC2 (Abcam, USA), S6K1 (Abcam, USA), p-S6K1 
(T389+T412) (Abcam USA), STAT3 (Abcam USA), phosphorylated STAT3 
(p-STAT3) (Cell signaling) and β-actin (Cell signaling). 
2.6 Real-time PCR 
According to the manufacturer’s protocol, RNA and DNA were isolated from cells 
with Ultrapure RNA Kit (CWBio) and TIANamp Genomic DNA Kit (TIANGEN), 
respectively. One microgram RNA was subjected to reverse transcription with 
Hiscript III RT SuperMix for qPCR (Vazyme), following the manufacturer’s protocol. 
As previously described 
[11]
, real-time polymerase chain reaction (PCR) was 
performed with the LightCycler
®
96 System (Roche Diagnostics GmbH, Roche 
Applied Science, Mannheim, Germany) using AceQ qPCR SYBR Green Master Mix 
(Vazyme). The primers of TSC2 were described below: 
5’-CGAGTCAAACAAGCCAATC-3’ (forward) and 
5’-ATCGTGCCAGCAGTAGGTG-3’ (reverse). PCR data were analyzed using Graph 
Pad Prism (Graph Pad Software, San Diego, California, USA). 
2.7 Literature Review 
Literature published between 1966 and June 1 2019, were searched in the Medline 
database. TSC AND kidney neoplasms (MeSH Terms) AND carcinoma renal cell 
(MeSH Terms) were used for searching related cases and articles. All RCC cases with 
TSC mutations were included in the review if they meet the following criteria: (i) 
RCC with TSC mutation; (ii) pathological examination was applied to verify the 
diagnosis; and (iii) gene mutations were analyzed and confirmed. 
Results  
3.1 biallelic somatic mutations were identified in a patient with RCC 
A diagnosis of T1N0M0 kidney tumor was made based on the heterogeneous 
enhancement of the mass in the abdominal computed tomography (CT) scan (Figure 
1A). Tumor samples from a patient with VHL syndrome showed specific ccRCC 
morphology characterized by transparent and empty cytoplasm, well-defined cell 
borders and thin-walled vessels. In the tumor samples of our patient with TSC2 
mutation, round and regular nuclei, cytoplasm with granular eosinophilic material 
around the nucleus and thin-walled vessels were shown in hematoxylin-eosin staining, 
suggesting a ccRCC, Furhman Grade 3 (Figure 1C). In addition, 
immunohistochemical staining results of the tumor samples with TSC2 mutation also 
showed positive CK, Vimentin, CD10, RCC staining, and negative CA9, CK7 and 
TFE-3 staining (data not shown). Two pathologists confirmed these results 
independently. 
Considering the early onset age and clinical characteristics, hereditary RCC should be 
identified. Susceptibility genes highly associated with RCC oncogenesis (supplement 
table 1 and supplement table 2) were examined in both peripheral blood and tumor 
samples. No germline mutations were observed, while two novel somatic mutations in 
TSC2 were identified in the tumor, but not the peripheral blood. These biallelic 
frameshift mutations were not found in the Catalogue Of Somatic Mutations In 
Cancer (http://cancer.sanger.ac.uk). Therefore we conclude that we identified a novel 
11-base deletion of 1039_1049 (c.1039-1049del AAGAAGTATAG) in exon 11 which 
leads to a frameshift (p.K347Efs*36) and a novel 1-base insertion at base 2721 
(c.2721insT ) in exon 24 which also leads to a frameshift (p.V909Cfs*6) (Figure 1B). 
Of note, no somatic nor germline mutation was found in the other oncogenesis genes 
examined (data are not shown). 
 
3.2 Higher p-S6K1 expression in tumor cells with mutant TSC2 
It appears that the frameshift mutations in either exon 11 or 24 of TSC2 would result 
in truncated TSC2 protein which might be loss-of-function. We have also noticed that 
in the tumor cells with TSC2 mutation the TSC2 staining is negative. On the contrary, 
the TSC2 staining in samples of another patient with VHL syndrome is positive. Next, 
we examined the levels of downstream of TSC2 (p-S6K1) in tumor samples. The 
results substantiated that the mutant TSC2 proteins were loss-of-function evidenced 
by positive staining of p-S6K1 in the patient with TSC2 mutations but negative 
staining with VHL syndrome. The VHL staining in both samples is positive with 
similar intensities (Fig 1C). In addition, the papillary renal cell carcinoma 
associated-gene SDHB is not only expressed but with comparable intensities in these 
samples (data not shown). 
3.3 The effect of TSC2 mutations on the levels of p-S6K1 and p-STAT3 in vitro 
To elucidate the relationship between the above-mentioned TSC2 mutations and RCC, 
we first tried to express either wild type or mutant TSC2 in TSC2-null cells by 
transient transfection of a plasmid expressing corresponding TSCs. The plasmids 
expressing either wild type or mutant TSC2 were successfully delivered to the cells 
and transcribed into their corresponding mRNAs evidenced by positive results from 
PCR (Figure 2B and 2C). However, only the wild type, but not the mutant, TSC2 
were detectable by western blot assays (Figure 2A). Since the results from PCR 
indicate that the transfected plasmids were successfully transcribed, we speculate that 
the mutant and presumably misfolded TSC2s is quickly degraded in the cells. 
Consequently, phosphorylation of STAT3 and S6K1 in TSC2-null cells were repressed 
only when they were transfected with the plasmid expressing the wild type, but not 
the mutant, TSC2. Of note, the levels of STAT3, S6K1, and β-actin were comparable 
among in these experiments. These results altogether suggest that the mutant TSC2 
might be quickly degraded and consequently lost repression of the downstream 
pathways, which ultimately leads to RCC oncogenesis 
[2-4]
. 
3.4 Literature Review 
Among the 59 articles retrieved by searching the Medline database published between 
(1969 and 2017), 33 were included in this review. In 1986, Graves et al reported the 
first case of TSC associated RCC 
[7]
. Since then, dozens of RCC cases associated with 
TSC have been reported although gene sequencing for the specific mutations was not 
conducted. In 1995, Sampson et al reported RCC accompanied with a TSC1 mutation 
in two sisters of the same family who also suffered from TSC 
[12]
. In 1996, Bjornsson 
et al reported a case of RCC in a patient with TSC due to a loss-of-heterozygosity 
(LOH) in TSC2 
[13]
. In 2011, Kucejova et al identified a somatic mutation in TSC1 in 
three cases of TSC-associated ccRCC 
[14]
. Not until 2015, have the first two cases of 
TSC-associated RCC with a somatic mutation in TSC2 been reported by Tyburczy et 
al. Also in the same article, the second-hit theory was introduced to explain TSC2 
inactivation 
[15]
. Samer Alsidawi et al described a patient with TSC2-associated 
metastatic RCC and showed the efficacy of mTOR inhibition in therapy 
[16]
. Seven 
patients with eosinophilic solid and cystic renal cell carcinoma were reported with 
somatic biallelic loss of TSC gene 
[17]
. So far, only 26 cases of RCC with TSC 
mutation have been reported and the characteristics of these patients were 
summarized in Table 1. 
Discussion  
Approximately 2-3% of RCC were considered as hereditary diseases, including von 
Hippel-Lindau (VHL) syndrome, hereditary papillary renal cell carcinoma and 
Birt-Hogg-Dube´ syndrome commonly 
[1]
. In addition, about 2-4% of TSC patients 
also suffer from RCC 
[2-4]
. It is well established that germline mutations in TSC1/2 can 
cause RCC 
[13, 18-20]
. Somatic inactivation of TSC1/2 either due to heterozygous loss of 
TSC1 or mutations in TSC1 and TSC2 occurs in 1–2% of adult RCC patients [21]. 
However, biallelic somatic inactivation of TSC2 associated RCC in an adolescent is 
rare. Here we reported RCC in a female adolescent with two novel somatic 
inactivating mutations in TSC2. Additionally, results from in vitro experiments 
demonstrated that the mutant TCS2s were incapable of repressing its downstream 
pathways.  
The classic two-hit theory is a widely accepted mechanism in the oncogenesis of 
patients with TSC 
[3, 6, 22]
. Tyburczy et al found that patients with TSC carrying 
germline mutations in TSC1 or TSC2. The second hit of the remaining allele was 
found in renal cell carcinoma 
[15]
. Potter et al reported two somatic TSC2 mutations in 
tumor samples from a 6-year-old female with RCC and methylmalonic acidemia 
[21]
. 
Our findings in this report also strongly support the two-hit theory. Of note, Tyburczy 
et al. conducted next-generation sequencing on DNAs purified from blood/saliva and 
some skin biopsy samples of 53 TSC patients. They found that the majority (26 of 45, 
58%) of the patients in this cohort have mosaic TSC mutations 
[23]
. Although two 
distinct TSC2 mutations have been identified in the tumor of the patient reported in this 
article, we cannot exclude the possibility that the tumor tissue is made of cells expressing the 
two TSC2 mutations mosaically. Together with TSC1, TSC2 forms a complex essential 
for GTPase-activating and by hydrolyzing GTP in RHEB to inactivate mTORC1 
pathway 
[24]
. Therefore, loss-of-function of TSC2 results in accumulation of 
GTP-RHEB and constitutive activation of mTORC1 which subsequently upregulates 
p-S6K1 and p-STAT3. Each of these factors plays important roles in the oncogenesis 
of renal cell carcinoma 
[25, 26]
. In the current case, we found that upregulated p-S6K1 
was accompanied by the mutations of TSC2 in immunohistochemical staining of the 
tumor sample. P-STAT3 and p-S6K1, the downstream targets of mTORC1, were 
significantly elevated in TSC2-null cells transfected with plasmids expressing the 
TSC2 mutants. These results suggest that TSC2 mutation-caused mTORC1 pathway 
over-activation could be the underlying molecular mechanism for the development of 
ccRCC. Although plasmids expressing either wide type or mutant TSC2 were 
successfully delivered and transcribed in TSC2-null cells (Figure 2B and 2C), the 
mutant TSC2s were undetectable in western blots. We hypothesized that the mutant 
TSC2s are misfolded and quickly degraded 
[27]
. However, this needs to be confirmed 
experimentally in future studies. 
Renal lesions are the most frequent manifestation in patients with TSC with 70-80% 
having angiomyolipomas, 20% with renal cysts although RCC is much less common 
[5]
. In RCC patients with familial TSC, tumors often occur bilaterally with a tendency 
of early-onset. The average onset of RCC in patients with TSC is 28-year-old, 25 
years earlier than that in the general population 
[28]
. The onset of RCC in the current 
case is 14, which is not only much earlier than that of the general population but also 
the average onset age in patients with TSC. Contrary to the general distribution 
pattern in most RCC patients with TSC, the tumor is unilateral (the left kidney) and 
solitary.  
RCC in TSC generally shows histological heterogeneity 
[29]
 with different subtypes of 
RCC including ccRCC, papillary RCC, chromophobe carcinoma, and oncocytomas 
[6]
. 
Among the 46 renal neoplasms from 19 TSC patients, Yang et al identified three 
subtypes: 52% are TSC-associated papillary RCC with a deficiency in succinate 
dehydrogenase subunit B (SDHB); 33% showed morphological features similar to a 
hybrid oncocytic/chromophobe tumor (HOCT), and 15% remained unclassifiable 
[4]
. 
However, Guo et al reported that among 57 RCCs from 18 patients with TSC, 59% of 
the tumor was similar to chromophobe RCC; 30% resemble “renal 
angiomyoadenomatous tumor” or “RCC with smooth muscle stroma”; 11% of the 
tumors exhibited a granular eosinophilic-macrocystic morphology 
[30]
. These findings 
suggest that TSC-associated RCC has distinctive pathological features. In the current 
case, a ccRCC subtype characterized by the regular nucleus, thin-walled vessels, 
positive CK, Vimentin, CD10, RCC staining and negative CA9, CK7, TFE-3 staining 
was confirmed by two independent pathologists. 
Inhibitors of the mTOR signaling pathway are FDA-approved therapeutic reagents for 
adult patients with relapsed or metastatic RCC 
[21]
. Multiple lines of evidence suggest 
that gene mutations in the mTOR pathway (including TSC1, TSC2, and mTOR) 
respond well to mTOR inhibition 
[30]
. Based on the elevated level of p-S6K1 and 
p-STAT3, we speculate that the mTOR pathway in the current case could be super 
active. Although no signs of recurrence nor metastatic in this patient were seen so far, 
we believe that mTOR inhibitor could be administered once the tumor recurs or the 
patient is under situations unsuitable for surgery. In summary, we reported a rare case 
of ccRCC with novel biallelic somatic mutations in TSC2. This provides new insight 
into the mechanism of RCC oncogenesis. In addition, genetic testing for a TSC2 
mutation in patients with early RCC onset could be beneficial in both diagnosis and 
therapy. Finally, mTOR inhibitor could be a therapeutic option for TSC2 
mutation-induced RCC. 
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Figure legend 
 
Figure 1. Characterization of TSC2 mutation-induced RCC. (A) Cross-section 
of the CT scan revealed an RCC in the left kidney of the patient with an arrow 
indicating the location of the tumor. (B) Sanger sequencing identified the TSC2 
mutations with arrows indicating the mutation sites. (C) Hematoxylin-eosin 
staining (100× and 400×) and immunohistochemical staining (400×) of VHL, 
TSC2, and p-S6K1 in the RCC samples from this patient with TSC2 mutations 
and another patient with VHL syndrome. 
 
 
 Figure 2. The efficiency of transfection, the expression, and the effects of the 
wild type and mutant TSC2. (A) The level of TSC2, as well as STAT3, 
p-STAT3, S6K1 and p-S6K1 in TSC2-null cells transfected with plasmids 
expressing wild type or mutant TSC2. (B and C) The efficiency of transfections 
(B) and transcription of TSC2 (C) when the cells were transfected with 
plasmids expressing wild type or mutant TSC2. 
 
 
 
 Table1. Published cases of RCC in patients with mutation in TSC1 or TSC2. 
ID Sex Age at 
onset 
Somatic/germline 
mutation in TSC 
Loss or 
mutation 
Mutation site Protein Histology Authors 
and year 
1 F 38 germline LOH in 
TSC1 
NA NA Clear cell 
renal cell 
carcinoma 
Bjornsson 
et al 
(1996)[13] 
2 M 23 germline LOH in 
TSC1 
NA NA Anaplastic and 
clear cell renal 
cell carcinoma 
Bjornsson 
et al 
(1996)[13] 
3 F 34 germline LOH in 
TSC2 
NA NA Anaplastic and 
clear cell renal 
cell carcinoma 
Bjornsson 
et al (1996) 
[13] 
4 M 7 Germline Mutation in 
TSC2 
c.1832G>A p.R611Q Renal cell 
carcinoma  
Pressey et 
al (2010)[18] 
5 NA NA Somatic  Mutation in 
TSC1 
c.1546C>T  p.Q516X clear cell renal 
cell carcinoma 
Kucejova 
et al 
(2011)[14] 
6 NA NA Somatic  Mutation in 
TSC1 
IVS211-2A>T Sp clear cell renal 
cell carcinoma 
Kucejova 
et al (2011) 
[14] 
7 NA NA Somatic Mutation in 
TSC1 
c.1342C>T p.P448S clear cell renal 
cell carcinoma 
Kucejova 
et al (2011) 
[14] 
8 F 3-month Germline  Mutation in 
TSC2 
NA NA Papillary renal 
cell carcinoma 
Kubo et al  
(2011)[19] 
9 M 
 
17-month Germline  Mutation in 
TSC2 
NA NA renal cell 
carcinoma 
Kubo et al  
(2011) [19] 
10 F 24 Germline and 
somatic 
Mutation in 
TSC2 
c.2714G>A (G);  
c.4051G>T (S);  
p.R905Q(G); 
p.E1351 (S) 
Papillary renal 
cell carcinoma 
Tyburczy et 
al (2015)[15]  
Mutation in 
TSC2 
c.2714G>A (G);  
c.4178_4179delCT 
(S) 
p.R905Q 
(G); 
 
Papillary renal 
cell carcinoma 
Tyburczy et 
al (2015)[15] 
Mutation in 
TSC2 
c.2714G>A (G);  
c.3094C>T (S)  
p.R905Q 
(G); 
p.R1032 (S) 
Papillary renal 
cell carcinoma 
Tyburczy et 
al (2015) 
[15] 
Mutation in 
TSC2 
c.2714G>A (G);  
c.5138G>A (S)  
p.R905Q 
(G); 
p.R1713H 
Papillary renal 
cell carcinoma 
Tyburczy et 
al (2015) 
[15] 
(S) 
LOH in 
TSC2 
c.2714G>A (G)  p.R905Q(G) Papillary renal 
cell carcinoma 
Tyburczy et 
al (2015) 
[15] 
11 M 36  Germline and 
somatic 
Mutation in 
TSC2 
c.2714G>A (G);  
c.2355+1G>T (S) 
p.R905Q (G) Papillary renal 
cell carcinoma 
Tyburczy et 
al (2015) 
[15] 
12 F 14 Germline Mutation in 
TSC1 
c.659T>A NA Renal cell 
carcinoma 
Peron et al 
(2016)[20] 
13 F 39 Germline Mutation in 
TSC1 
c.458T>A NA Chromophobe 
renal cell 
carcinoma 
Peron et al 
(2016) [20] 
14 F 41 Germline Mutation in c.458T>A NA Chromophobe Peron et al 
TSC1 renal cell 
carcinoma 
(2016) [20] 
15 F 16 Germline Mutation in 
TSC1 
c.547_571del25 NA Clear cell 
renal cell 
carcinoma 
Peron et al 
(2016) [20] 
16 M NA Germline Mutation in 
TSC1 
c.2681_2682delAT NA Renal 
oncocytoma 
Peron et al 
(2016) [20] 
17 F 25 Germline Mutation in 
TSC2 
c.1852delC NA Clear cell 
renal cell 
carcinoma 
Peron et al 
(2016) [20] 
18 F 6 Somatic  Mutation in 
TSC2 
c.246G>A; 
c.3370_3382del 
p.W82X; 
p.A1124fs 
renal cell 
carcinoma 
Potter et al  
(2017)[21] 
19 M 47 Germline Mutation in c.4859A>G p.H1620R papillary RCC Alsidawi et 
TSC2 c.4949A>G p.Y1650C al 
(2018)[16] 
20 NA NA Somatic Mutation in 
TSC2 
NA p.L741fs 
p.K533Splice 
eosinophilic  
solid  and  
cystic  RCC 
Mehra et al 
(2018)[17] 
21 NA NA Somatic LOH in 
TSC2 
NA p.C519fs eosinophilic  
solid  and  
cystic  RCC 
Mehra et al 
(2018) [17] 
22 NA NA Somatic LOH in 
TSC2 
NA p.Y349fs eosinophilic  
solid  and  
cystic  RCC 
Mehra et al 
(2018) [17] 
23 NA NA Somatic Mutation in 
TSC2 
NA p.L773* 
p.N1250fs 
eosinophilic  
solid  and  
Mehra et al 
(2018) [17] 
cystic  RCC 
24 NA NA Somatic Nonesense NA p.S9* eosinophilic  
solid  and  
cystic  RCC 
Mehra et al 
(2018) [17] 
25 NA NA Somatic LOH in 
TSC1 
NA p.Y176fs eosinophilic  
solid  and  
cystic  RCC 
Mehra et al 
(2018) [17] 
26 NA NA Somatic Mutation in 
TSC1 
NA p.Q653* 
p.Q696fs 
eosinophilic  
solid  and  
cystic  RCC 
Mehra et al 
(2018) [17] 
Abbreviations: F: Female, G: Germline; LOH: Loss of heterozygosity; M: male; NA: Not Available; S: Somatic; TSC: Tuberous 
Sclerosis Complex. 
 
 
